FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec 18, 2025--
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company’s senior leadership team and report to Chairman and Chief Executive Officer Daniel O’Day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/
Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Partners team. She previously led the Litigation and Government Investigations and the Corporate Governance and Strategic Transactions teams. Ms. Wettan has been instrumental in supporting the launch of groundbreaking medicines, including the recent launch of lenacapavir, a breakthrough twice-yearly HIV prevention medicine. She also currently serves as the Chair of the Board of the Gilead Foundation.
“Keeley is an accomplished executive who brings deep legal expertise, and who leads with integrity, passion and commitment to the people and communities we serve,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “During her 14-year career with Gilead, Keeley has helped to drive some of our most important progress from the launch of groundbreaking new medicines to pioneering access agreements. I am confident that Keeley will be an excellent addition to the Gilead Leadership Team as we continue to deliver on the strongest pipeline in our history.”
Prior to joining Gilead, Keeley was an attorney at the law firm Simpson Thacher & Bartlett in New York City where her practice focused on general litigation and government investigations. Keeley received her J.D. from the University of California at Berkeley.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.
For more information about Gilead, please visit the company’s website atwww.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
FRANKFURT, Germany (AP) — The European Central Bank left interest rates unchanged Thursday for the fourth meeting in a row as the economy in the 20 countries that use the euro increasingly looks strong enough to get by without the stimulus of lower borrowing costs for businesses and consumers.
The bank’s rate-setting council left the benchmark deposit rate unchanged at 2%, where it has been since a rate cut in June. Economists now think the rate could stay there for months - and possibly into 2027.
That’s because the ECB remains poised between inflation that’s just a bit too persistent and growth that’s underwhelming but steady after a trade deal with the US remove some of the uncertainty that had held back business planning. Higher rates fight inflation while cuts support growth.
The bank said in a statement following the decision that economic growth “is expected to be stronger” than in the bank's last projections in September, while inflation in services businesses was declining more slowly, even as overall inflation was expected to stabilize at the bank's 2% target.
Surveys of purchasing managers by S&P Global slipped slightly for December but still showed business activity expanding as the year comes to an end, reinforcing expectations that the 20 countries using the euro currency will continue to see growth of around 0.3% per quarter over the previous quarter, said Adrian Prettejohn, Europe economist at Capital Economics.
That outcome is better than feared during turbulent trade negotiations with the United States over the summer, which finally settled with a 15% tariff, or import tax, imposed on European goods by U.S. President Donald Trump.
That is not great for European exporters. But Trump had threatened higher rates and the deal struck with the European Union's executive commission appears to have removed uncertainty and made it easier for businesses to make decisions.
So the economy can get by without the added boost from a cut, analysts say.
“The haze of economic uncertainty has somewhat lifted, especially regarding trade,” economist Lorenzo Codogno said.
On top of that, inflationary pressures remain too high for the ECB to contemplate a cut.
The headline rate of 2.1% for annual inflation in November is roughly in line with the bank's goal of 2%, thanks in part to a drop in volatile energy prices. But inflation was higher at 3.5% in the services sector, which encompasses much of the economy from hairdressers and hotels to concert tickets and medical services.
While the ECB stood pat, the Bank of England on Thursday cut its key interest rate for the first time in four months as stubbornly high inflation starts to ease. Policymakers voted 5-4 to reduce the base rate by a quarter of a percentage point to 3.75% on Thursday. Consumer price inflation slowed to 3.2% in the 12 months through November, from 3.6% a month earlier.
Central bank rate cuts can support growth because they strongly influence borrowing rates throughout the economy, lowering credit costs and promoting credit sensitive purchases such as new homes by consumers or new production facilities by businesses. Higher rates have the opposite effect and are used to contain inflation by dampening demand for goods.
FILE - The European Central Bank is seen near the river Main in Frankfurt, Germany, early Tuesday, Dec. 9, 2025. (AP Photo/Michael Probst, File)
